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1. Introduction 
AMP polynucleotidylexotransferase from corn 
seedlings [ 11, an enzyme catalyzing the sequential 
addition of AMP moieties to the 3’ hydroxyl terminus 
of an oligonucleotide primer to form poly(A) [2], is 
inhibited by rifampicin and rifampicin derivatives with 
modified aminopiperazine side chains [3]. We report 
here a similar sensitivity of the tRNA-primed exotrans- 
ferase partially purified from HeLa S3 cells [4]. The 
aminopiperazine derivatives of rifampicin are known 
to preferentially inhibit and thus bind RNA tumor 
viral reverse transcriptase as compared with their inhi- 
bition of RNA and DNA-dependent polymerases [5]. 
2. Methods and materials 
AMP polynucleotidylexotransferase was prepared 
from a post-ribosomal supernatant of an homogenate 
of exponentially growing HeLa S3 cells by ammonium 
sulfate precipitation and DEAE-cellulose chromato- 
graphy as described previously [4]. The activity was 
determined by measuring the accumulation of acid- 
insoluble radioactivity from labeled ATP. A reaction 
mixture (0.1 ml) containing 7 pmoles Tris (pH 8.8), 
1 pmole dithiothreitol, 0.12 qole [8-14C]ATP 
(1.5 mCi/mmole), 10 pg bovine serum albumin, 
0.1 pmole MnCl,, 6.2 pg enzyme and the appropriate 
primer was incubated at 30°C. Aliquots were removed 
after 30, 60, and 90 min, delivered to filter paper disks 
and the total AMP incorporated into acid-insoluble 
material determined as described previously [2]. With 
tRNA as primer the enzyme catalyzed the addition of 
47 nmoles AMP/mg/min under these conditions. 
North-Holland Publishing Company - Amsterdam 
The synthetic oligomers were purchased from PL 
Biochemicals, Inc., Milwaukee, Wise., the tRNA of 
Escherichia coli and the ATP from Schwarz-Mann, 
Orangeburg, N.Y. The rifampicin and aminopiperazine 
derivatives were generously donated by Gruppo Lepetit 
spa, Milan. 
3. Results 
The sensitivity of the HeLa exotransferase to rifam- 
picin SV and aminopiperazine derivatives of rifampicin 
is similar to that reported for several RNA tumor virus 
reverse transcriptases by Curgo et al. [5]. The 2,5-de- 
methyl-4-N-benzyl demethyl rifampicin is most effec- 
tive (50% inhibition at 160 pug/ml) inhibitor of the 
tRNA-primed HeLa exotransferase (fig. 1, panel A). 
The level of sensitivity of the exotransferase to rifam- 
picin SV is similar to that of the DNA-dependent 
RNA polymerase of Ehrlich ascites carcinoma cells 
reported by Umezawa et al. [6]. 
In distinguishing reverse transcriptase of an RNA 
tumor virus from eukaryotic DNA polymerases, 
(dT)ru.poly(A) is a preferred synthetic duplex as com- 
pared with (dT)l,,.poly(dA) [7]. The HeLa exotrans- 
ferase exhibits a similar preference for (dT)lo.poly(A). 
See table 1. Of further interest is the inhibition of the 
low level of AMP incorporation in the absence of 
added primer upon the addition of (dT)I,,.poly(A) or 
poly(dT)lo. The inhibition of the exotransferase by 
deoxyoligomers appears to be the antithesis of the in- 
hibition of the Rauscher leukemia virus reverse tran- 
scriptase by polyribonucleotides reported by Tuominen 
and Kenney [8]. The (dT)lo.poly(A) primed reaction 
with the HeLa exotransferase xhibits essentially the 
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Fig. 1. Inhibition of HeLa exotransferase by rifampicin and 
aminopiperazine derivatives. Reaction mixtures as described 
in Methods and materials but containing: 0.5 pg dimethylsul- 
foxide, the indicated amount of rifampicin SV (-), 
N-dimethyl rifampicin AF/AP (m ) or 2,5-dimethyl-4- 
N-benzyl demethyl rifampicin AF/ABDMP (-) and 
0.41 AZ@ l?. coli tRNA (panel A) or 0.05 Aaeo (dT.poly(A) 
as primer (panel B) were incubated at 30°C. In the absence 
of drug, 0.7, 3.1 and 7.0 nmoles AMP were incorporated into 
acid-insoluble material with tRNA in 30, 60 and 90 min, 
respectively. 1.5,4.5 and 8.8 nmoles AMP were incorporated 
in the (dT)to.poly(A)-primed reaction in 30, 60 and 90 min, 
respectively. The percent activity remaining at each time point 
was within 1.5% of the mean of all three time points with a 
given concentration of a given drug. 
Table 1 
Effect of various primers on the level of AMP incorporated in- 
to acid-insoluble material by HeLa exotransferase. 
Primer Amount 
added 
(A260) 
Poly (A) 
synthesized 
(nmole AMP) 
tRNA 0.21 7.4 
(dT) to’ poly(A) 0.05 9.8 
(dT)to.poly(A) 0.25 17.3 
(dT)to.poly(dA) 0.25 0.5 
Poly (A) 0.09 18.5 
Poly(dT)to 0.25 0.2 
None _ 0.9 
Reaction mixtures as described in Methods and materials con- 
taining the indicated oligomers were incubated at 30” C for 90 
min. The total nmoles of radioactive AMP incorporated into 
acid-insoluble material was determined on filter paper disks as 
described previously [2]. 2466 cpm was equivalent to nmole 
AMP. 
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same sensitivity to the aminopiperazine derivatives of 
rifampicin as the tRNA-primed reaction (cf. panel B 
with panel A in fig. 1). However, the reaction primed 
with the synthetic duplex is more sensitive to rifam- 
picin SV than the reaction primed with the double 
stranded tRNA. 
4. Discussion 
These somewhat surprising observations indicate 
that a non-template requiring, rioonucleotide poly- 
merizing activity (AMP polynucleotidylexotransferase) 
can be inhibited by drugs, heretofore thought specific 
for a template-requiring, deoxyribonucleotide poly- 
merizing enzyme (reverse transcriptase). Furthermore, 
the dual primer-template function of (dT)to.poly(A), 
although true for the reverse transcriptase reaction is 
not requisite for its preferential use by an enzyme 
adding AMP moieties to the primer poly(A) portion 
of the duplex. Alternatively, the AMP polynucleotidyl- 
exotransferase may be among the polypeptide com- 
ponents of a functional reverse transcriptase [9] and 
those associated with eukaryotic mRNA’s [IO]. 
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